Investor Relations

Latest Financial Results

Q2 2016

Quarterly Results

Ended Mar 31, 2016

Stock Information

OTCBB: AVDX Avant Diagnostics, Inc.
Day Range
52 Week Range

Company Overview

Avant is a medical diagnostic technology company that specializes in large panel biomarker tests. Our first test, OvaDx®, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx®. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.

Contact Information

Transfer Agent
Signature Stock Transfer, Inc.
2632 Coachlight Court
Plano, TX 75075
T: 972-612-4120

Sign up for email updates

Be the first to receive news and updates

Learn More